메뉴 건너뛰기




Volumn 1, Issue 2, 2004, Pages 289-304

CTLA4-Ig fusion proteins: Promise for improved therapy of transplant rejection and autoimmune diseases

Author keywords

Autoimmune diseases; CD28 antagonist; CD28 B7 pathway; CTLA4 Ig; Immune tolerance; Immunosuppression; LEA29Y; Psoriasis; Rheumatoid arthritis; T cell costimulation; Transplant rejection

Indexed keywords

ABATACEPT; ADALIMUMAB; ALEFACEPT; B7 ANTIGEN; BASILIXIMAB; BELATACEPT; CD28 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 FUSION PROTEIN; DACLIZUMAB; EFALIZUMAB; ETANERCEPT; EVEROLIMUS; GLUCOCORTICOID; IMMUNOGLOBULIN G; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; OKT 3; PLACEBO; RAPAMYCIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; T LYMPHOCYTE RECEPTOR; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG;

EID: 21244482393     PISSN: 14750708     EISSN: None     Source Type: Journal    
DOI: 10.1586/14750708.1.2.289     Document Type: Review
Times cited : (1)

References (138)
  • 1
    • 0038318967 scopus 로고    scopus 로고
    • Immunosuppressants in advanced clinical development for organ transplantation and selected autoimmune diseases
    • Kovarik JM, Burtin P. Immunosuppressants in advanced clinical development for organ transplantation and selected autoimmune diseases. Expert Opin. Emerg. Drugs 8, 47-62 (2003).
    • (2003) Expert Opin. Emerg. Drugs , vol.8 , pp. 47-62
    • Kovarik, J.M.1    Burtin, P.2
  • 2
    • 0042971650 scopus 로고    scopus 로고
    • Molecular interactions mediating T-cell antigen recognition
    • van der Merwe PA, Davis SJ. Molecular interactions mediating T-cell antigen recognition. Annu. Rev. Immunol. 21, 659-684 (2003).
    • (2003) Annu. Rev. Immunol. , vol.21 , pp. 659-684
    • van der Merwe, P.A.1    Davis, S.J.2
  • 4
    • 0038171458 scopus 로고    scopus 로고
    • Activation-induced cell death in T-cells
    • Green DR. Droin N, Pinkoski M. Activation-induced cell death in T-cells. Immunol. Rev. 193, 70-81 (2003).
    • (2003) Immunol. Rev. , vol.193 , pp. 70-81
    • Green, D.R.1    Droin, N.2    Pinkoski, M.3
  • 5
    • 0036072614 scopus 로고    scopus 로고
    • Targeting T-cell costimulation in autoimmune disease
    • Racke MK, Stuart RW. Targeting T-cell costimulation in autoimmune disease. Expert. Opin. Ther. Targets 6, 275-289 (2002).
    • (2002) Expert. Opin. Ther. Targets , vol.6 , pp. 275-289
    • Racke, M.K.1    Stuart, R.W.2
  • 8
    • 0027403299 scopus 로고
    • The role of the CD28 receptor during T-cell responses to antigen
    • Linsley PS, Ledbetter JA. The role of the CD28 receptor during T-cell responses to antigen. Ann. Rev. Immunol. 11, 191-212 (1993).
    • (1993) Ann. Rev. Immunol. , vol.11 , pp. 191-212
    • Linsley, P.S.1    Ledbetter, J.A.2
  • 10
    • 0035059417 scopus 로고    scopus 로고
    • Complexities of CD28/B7:CTLA-4 costimulatory pathways in autoimmunity and transplantation
    • Salomon B, Bluestone JA. Complexities of CD28/B7:CTLA-4 costimulatory pathways in autoimmunity and transplantation. Ann. Rev. Immunol. 19, 225-252 (2001).
    • (2001) Ann. Rev. Immunol. , vol.19 , pp. 225-252
    • Salomon, B.1    Bluestone, J.A.2
  • 11
    • 0347505003 scopus 로고    scopus 로고
    • CD28-mediated co-stimulation: A quantitative support for TCR signalling
    • Acuto O, Michel F. CD28-mediated co-stimulation: a quantitative support for TCR signalling. Nature Rev. Immunol. 3, 939-951 (2003).
    • (2003) Nature Rev. Immunol. , vol.3 , pp. 939-951
    • Acuto, O.1    Michel, F.2
  • 12
    • 0026778697 scopus 로고
    • Immunosuppression in vivo by a soluble form of the CTLA-4 T-cell activation molecule
    • Linsley PS, Wallace PM, Johnson J. et al. Immunosuppression in vivo by a soluble form of the CTLA-4 T-cell activation molecule. Science 257, 792-795 (1992).
    • (1992) Science , vol.257 , pp. 792-795
    • Linsley, P.S.1    Wallace, P.M.2    Johnson, J.3
  • 13
    • 0028675006 scopus 로고
    • Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors
    • Linsley PS, Greene JL, Brady W et al. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1, 793-801 (1994).
    • (1994) Immunity , vol.1 , pp. 793-801
    • Linsley, P.S.1    Greene, J.L.2    Brady, W.3
  • 14
    • 0027937702 scopus 로고
    • Complementary determining region 1 (CDR1) - CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1
    • Peach RJ, Bajorath J, Brady W et al. Complementary determining region 1 (CDR1) - CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1. J. Exp. Med. 180, 2049-2058 (1994).
    • (1994) J. Exp. Med. , vol.180 , pp. 2049-2058
    • Peach, R.J.1    Bajorath, J.2    Brady, W.3
  • 15
    • 0031180381 scopus 로고    scopus 로고
    • Solution structure of human CTLA-4 and delineation of a CD80/CD86 binding site conserved in CD28
    • Metzler WJ, Bajorath J, Fenderson W et al. Solution structure of human CTLA-4 and delineation of a CD80/CD86 binding site conserved in CD28. Nature Struct. Biol. 4, 527-531 (1997).
    • (1997) Nature Struct. Biol. , vol.4 , pp. 527-531
    • Metzler, W.J.1    Bajorath, J.2    Fenderson, W.3
  • 16
    • 0035967146 scopus 로고    scopus 로고
    • Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses
    • Stamper CC, Zhang Y, Tobin JF et al. Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses. Nature 410, 608-611 (2001).
    • (2001) Nature , vol.410 , pp. 608-611
    • Stamper, C.C.1    Zhang, Y.2    Tobin, J.F.3
  • 17
    • 0035967157 scopus 로고    scopus 로고
    • Structural basis for co-stimulation by the human CTLA-4/B7-2 complex
    • Schwartz JC, Zhang X, Fedorov AA, Nathenson SG, Almo SC. Structural basis for co-stimulation by the human CTLA-4/B7-2 complex. Nature 410, 604-608 (2001).
    • (2001) Nature , vol.410 , pp. 604-608
    • Schwartz, J.C.1    Zhang, X.2    Fedorov, A.A.3    Nathenson, S.G.4    Almo, S.C.5
  • 18
    • 0031036085 scopus 로고    scopus 로고
    • CD80 costimulation is essential for the induction of airway eosinophilia
    • Harris N, Peach R, Naemura J. et al. CD80 costimulation is essential for the induction of airway eosinophilia. J. Exp. Med. 185, 177-182 (1997).
    • (1997) J. Exp. Med. , vol.185 , pp. 177-182
    • Harris, N.1    Peach, R.2    Naemura, J.3
  • 19
    • 0035871614 scopus 로고    scopus 로고
    • CD80 costimulation is required for Th2 cell cytokine production but not for antigen-specific accumulation and migration into the lung
    • Harris NL, Prout M, Peach RJ, Fazekas De St Groth B, Ronchese F. CD80 costimulation is required for Th2 cell cytokine production but not for antigen-specific accumulation and migration into the lung. J. Immunol. 166, 4908-4914 (2001).
    • (2001) J. Immunol. , vol.166 , pp. 4908-4914
    • Harris, N.L.1    Prout, M.2    Peach, R.J.3    Fazekas De St Groth, B.4    Ronchese, F.5
  • 20
    • 0036499924 scopus 로고    scopus 로고
    • Blockade of CD28/B7-2 costimulation inhibits experimental obliterative bronchiolitis in rat tracheal allografts: Suppression of helper t-cell type 1-dominated immune response
    • Tikkanen JM, Lemstrom KB, Koskinen PK. Blockade of CD28/B7-2 costimulation inhibits experimental obliterative bronchiolitis in rat tracheal allografts: suppression of helper t-cell type 1-dominated immune response. Am. J. Respir. Crit. Care Med. 165, 724-729 (2002).
    • (2002) Am. J. Respir. Crit. Care Med. , vol.165 , pp. 724-729
    • Tikkanen, J.M.1    Lemstrom, K.B.2    Koskinen, P.K.3
  • 21
    • 33645444469 scopus 로고    scopus 로고
    • Soluble CTLA4 mutant molecules and uses thereof
    • Patent. WO0192337, (2001-12-06)
    • Bajorath J, Linsley PS, Peach RJ, Naemura JR. Soluble CTLA4 mutant molecules and uses thereof. Patent. WO0192337, (2001-12-06) (2001).
    • (2001)
    • Bajorath, J.1    Linsley, P.S.2    Peach, R.J.3    Naemura, J.R.4
  • 22
    • 33645429990 scopus 로고    scopus 로고
    • Antibodies and immunoglobulin fusion proteins having modified effector fanctions and uses therefor
    • Patent. WO9728267, 1997-08-07
    • Gray GS, Siver S, Carson J. et al. Antibodies and immunoglobulin fusion proteins having modified effector fanctions and uses therefor. Patent. WO9728267, 1997-08-07 (1997).
    • (1997)
    • Gray, G.S.1    Siver, S.2    Carson, J.3
  • 23
    • 0038546813 scopus 로고    scopus 로고
    • Mammary gland-specific secretion of biologically active immunosuppressive agent cytotoxic-T-lymphocyte antigen 4 human immunoglobulin fusion protein (CTLA4Ig) in milk by transgenesis
    • Lui VC, Tam PK, Leung MY et al. Mammary gland-specific secretion of biologically active immunosuppressive agent cytotoxic-T-lymphocyte antigen 4 human immunoglobulin fusion protein (CTLA4Ig) in milk by transgenesis. J. Immunol. Methods 277, 171-183 (2003).
    • (2003) J. Immunol. Methods , vol.277 , pp. 171-183
    • Lui, V.C.1    Tam, P.K.2    Leung, M.Y.3
  • 24
    • 0029916381 scopus 로고    scopus 로고
    • A pharmacokinetic study of intravenous CTLA4Ig, a novel immunosuppressive agent, in mice
    • Srinivas NR, Weiner RS, Shyu WC et al. A pharmacokinetic study of intravenous CTLA4Ig, a novel immunosuppressive agent, in mice. J. Pharm. Sci. 85, 296-298 (1996).
    • (1996) J. Pharm. Sci. , vol.85 , pp. 296-298
    • Srinivas, N.R.1    Weiner, R.S.2    Shyu, W.C.3
  • 25
    • 0030805029 scopus 로고    scopus 로고
    • Assessment of dose proportionality, absolute bioavailability, and immunogenicity response of CTLA4Ig (BMS-188667), a novel immunosuppressive agent, following subcutaneous and intravenous administration to rats
    • Srinivas NR, Shyu WC, Weiner RS et al. Assessment of dose proportionality, absolute bioavailability, and immunogenicity response of CTLA4Ig (BMS-188667), a novel immunosuppressive agent, following subcutaneous and intravenous administration to rats. Pharm. Res. 14, 911-916 (1997).
    • (1997) Pharm. Res. , vol.14 , pp. 911-916
    • Srinivas, N.R.1    Shyu, W.C.2    Weiner, R.S.3
  • 26
    • 0029661755 scopus 로고    scopus 로고
    • Pharmacokinetics and pharmacodynamics of CTLA4Ig (BMS-188667), a novel immunosuppressive agent, in monkeys following multiple doses
    • Srinivas NR, Weiner RS, Warner G et al. Pharmacokinetics and pharmacodynamics of CTLA4Ig (BMS-188667), a novel immunosuppressive agent, in monkeys following multiple doses. J. Pharm. Sci. 85, 1-4 (1996).
    • (1996) J. Pharm. Sci. , vol.85 , pp. 1-4
    • Srinivas, N.R.1    Weiner, R.S.2    Warner, G.3
  • 27
    • 0033135564 scopus 로고    scopus 로고
    • CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris
    • Abrams JR, Lebwohl MG, Guzzo CA et al. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J. Clin. Invest. 103, 1243-1252 (1999).
    • (1999) J. Clin. Invest. , vol.103 , pp. 1243-1252
    • Abrams, J.R.1    Lebwohl, M.G.2    Guzzo, C.A.3
  • 28
    • 0036852242 scopus 로고    scopus 로고
    • When ligand becomes receptor-tolerance via B7 signaling on DCs
    • Finger EB, Bluestone JA. When ligand becomes receptor-tolerance via B7 signaling on DCs. Nature Immunol. 3, 1056-1057 (2002).
    • (2002) Nature Immunol. , vol.3 , pp. 1056-1057
    • Finger, E.B.1    Bluestone, J.A.2
  • 29
    • 0027397169 scopus 로고
    • Induction of alloantigen-specific hyporesponsiveness in human T-lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1
    • Tan P, Anasetti C, Hansen JA et al. Induction of alloantigen-specific hyporesponsiveness in human T-lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1. J. Exp. Med. 177, 165-173 (1993).
    • (1993) J. Exp. Med. , vol.177 , pp. 165-173
    • Tan, P.1    Anasetti, C.2    Hansen, J.A.3
  • 30
    • 0041474771 scopus 로고    scopus 로고
    • The effects of B7-dependent costimulation on T-cell division and survival in vivo and in vitro are dependent on antigen concentration
    • Lumsden JM, Prasad SJ, Peach RJ, Ronchese F. The effects of B7-dependent costimulation on T-cell division and survival in vivo and in vitro are dependent on antigen concentration. Eur. J. Immunol. 33, 2074-2082 (2003).
    • (2003) Eur. J. Immunol. , vol.33 , pp. 2074-2082
    • Lumsden, J.M.1    Prasad, S.J.2    Peach, R.J.3    Ronchese, F.4
  • 31
    • 33645430129 scopus 로고    scopus 로고
    • Abatacept (CTLA4Ig; BMS-188667) significantly inhibits the proliferation of human T-cells in vitro at clinically relevant concentrations
    • Federation of Clinical Immunology Societies Meeting, Montreal Canada. Abs. 3514
    • Nadler S, Townsend R, Mikesell G et al. Abatacept (CTLA4Ig; BMS-188667) significantly inhibits the proliferation of human T-cells in vitro at clinically relevant concentrations. Federation of Clinical Immunology Societies Meeting, Montreal Canada. Abs. 3514 (2004).
    • (2004)
    • Nadler, S.1    Townsend, R.2    Mikesell, G.3
  • 32
    • 0029871741 scopus 로고    scopus 로고
    • The in vivo mechanism of action of CTLA4Ig
    • Judge TA, Tang A, Spain LM et al. The in vivo mechanism of action of CTLA4Ig. J. Immunol. 156, 2294-2299 (1996).
    • (1996) J. Immunol. , vol.156 , pp. 2294-2299
    • Judge, T.A.1    Tang, A.2    Spain, L.M.3
  • 33
    • 0029665801 scopus 로고    scopus 로고
    • The time course of CTLA4Ig effect on cardiac allograft rejection
    • Bolling SF, Lin H, Turka LA. The time course of CTLA4Ig effect on cardiac allograft rejection. J. Surg. Res. 63, 320-323 (1996).
    • (1996) J. Surg. Res. , vol.63 , pp. 320-323
    • Bolling, S.F.1    Lin, H.2    Turka, L.A.3
  • 34
    • 0012465040 scopus 로고    scopus 로고
    • Different mechanisms of cardiac allograft rejection in wildtype and CD28-deficient mice
    • Szot GL, Zhou P, Rulifson I et al. Different mechanisms of cardiac allograft rejection in wildtype and CD28-deficient mice. Am. J. Transplant. 1, 38-46 (2001).
    • (2001) Am. J. Transplant. , vol.1 , pp. 38-46
    • Szot, G.L.1    Zhou, P.2    Rulifson, I.3
  • 38
    • 0030461047 scopus 로고    scopus 로고
    • CD28-B7 T-cell co-stimulatory blockade by CTLA4Ig in the rat renal allograft model. inhibition of cell mediated and humoral immune responses in vivo
    • Akalin E, Chandraker A, Russell ME et al. CD28-B7 T-cell co-stimulatory blockade by CTLA4Ig in the rat renal allograft model. inhibition of cell mediated and humoral immune responses in vivo. Transplantation 62, 1942-1945 (1996).
    • (1996) Transplantation , vol.62 , pp. 1942-1945
    • Akalin, E.1    Chandraker, A.2    Russell, M.E.3
  • 39
    • 0029834883 scopus 로고    scopus 로고
    • Suppression of T-cell-dependent immune responses in monkeys by CTLA4Ig
    • Cabrian KM, Berry KK, Shuford WW et al. Suppression of T-cell-dependent immune responses in monkeys by CTLA4Ig. Transplant. Proc. 28, 3261-3262 (1996).
    • (1996) Transplant. Proc. , vol.28 , pp. 3261-3262
    • Cabrian, K.M.1    Berry, K.K.2    Shuford, W.W.3
  • 40
    • 0029856233 scopus 로고    scopus 로고
    • CTLA4Ig inhibits alloantibody responses to repeated blood transfusions
    • Ibrahim S, Jakobs F, Kittur D et al. CTLA4Ig inhibits alloantibody responses to repeated blood transfusions. Blood 88, 4594-4600 (1996).
    • (1996) Blood , vol.88 , pp. 4594-4600
    • Ibrahim, S.1    Jakobs, F.2    Kittur, D.3
  • 41
    • 0142213315 scopus 로고    scopus 로고
    • CTLA4-Ig abrogates die anti-globulin response and prolongs cardiac allograft survival after anti-CD2 treatment
    • Stell D, Marshall H, Bradley JA, Bolton EM. CTLA4-Ig abrogates die anti-globulin response and prolongs cardiac allograft survival after anti-CD2 treatment. Transpl. Immunol. 12, 1-7 (2003).
    • (2003) Transpl. Immunol. , vol.12 , pp. 1-7
    • Stell, D.1    Marshall, H.2    Bradley, J.A.3    Bolton, E.M.4
  • 43
    • 0033932756 scopus 로고    scopus 로고
    • CTLA4Ig inhibits T-cell-dependent B-cell maturation in murine systemic lupus erythematosus
    • Mihara M, Tan I, Chuzhin Y et al. CTLA4Ig inhibits T-cell-dependent B-cell maturation in murine systemic lupus erythematosus. J. Clin. Invest. 106, 91-101 (2000).
    • (2000) J. Clin. Invest. , vol.106 , pp. 91-101
    • Mihara, M.1    Tan, I.2    Chuzhin, Y.3
  • 44
    • 0026738641 scopus 로고
    • Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig
    • Lenschow DJ, Zeng Y, Thistlewaite JR et al. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig. Science 257, 789-792 (1992).
    • (1992) Science , vol.257 , pp. 789-792
    • Lenschow, D.J.1    Zeng, Y.2    Thistlewaite, J.R.3
  • 45
    • 0028365181 scopus 로고
    • Transplantation tolerance induced by CILA4-Ig
    • Pearson TC, Alexander DZ, Winn KJ et al. Transplantation tolerance induced by CILA4-Ig. Transplantation 57, 1701-1706 (1994).
    • (1994) Transplantation , vol.57 , pp. 1701-1706
    • Pearson, T.C.1    Alexander, D.Z.2    Winn, K.J.3
  • 46
    • 0028903939 scopus 로고
    • CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2
    • Sayegh MH, Akalin E, Hancock WW et al. CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2. J. Exp. Med. 181, 1869-1874 (1995).
    • (1995) J. Exp. Med. , vol.181 , pp. 1869-1874
    • Sayegh, M.H.1    Akalin, E.2    Hancock, W.W.3
  • 47
    • 0030293507 scopus 로고    scopus 로고
    • Toxic shock syndrome toxin-1-induced death is prevented by CTLA4Ig
    • Saha B, Jaklic B, Harlan DM et al. Toxic shock syndrome toxin-1-induced death is prevented by CTLA4Ig. J. Immunol. 157, 3869-3875 (1996).
    • (1996) J. Immunol. , vol.157 , pp. 3869-3875
    • Saha, B.1    Jaklic, B.2    Harlan, D.M.3
  • 48
    • 0038784372 scopus 로고    scopus 로고
    • Effects of B7-blocking agent and/or CsA on induction of platelet-specific T-cell anergy in chronic autoimmune thrombocytopenic purpura
    • Peng J, Liu C, Liu D et al. Effects of B7-blocking agent and/or CsA on induction of platelet-specific T-cell anergy in chronic autoimmune thrombocytopenic purpura. Blood 101, 2721-2726 (2003).
    • (2003) Blood , vol.101 , pp. 2721-2726
    • Peng, J.1    Liu, C.2    Liu, D.3
  • 49
    • 0026459468 scopus 로고
    • T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo
    • Turka LA, Linsley PS, Bradt W et al. T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc. Natl. Acad. Sci. USA 89, 11102-11105 (1992).
    • (1992) Proc. Natl. Acad. Sci. USA , vol.89 , pp. 11102-11105
    • Turka, L.A.1    Linsley, P.S.2    Bradt, W.3
  • 50
    • 0029060729 scopus 로고
    • Induction and reversal of long-lived specific unresponsiveness to a T-dependent antigen following CTLA4Ig treatment
    • Wallace PM, Rodgers JN, Leytze GM, Johnson JS, Linsley PS. Induction and reversal of long-lived specific unresponsiveness to a T-dependent antigen following CTLA4Ig treatment. J. Immunol. 11, 5885-5895 (1995).
    • (1995) J. Immunol. , vol.11 , pp. 5885-5895
    • Wallace, P.M.1    Rodgers, J.N.2    Leytze, G.M.3    Johnson, J.S.4    Linsley, P.S.5
  • 51
    • 0027451441 scopus 로고
    • Long term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion
    • Lin H, Boiling SF, Linsley PS et al. Long term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion. J. Exp. Med. 178, 1801-1806 (1993).
    • (1993) J. Exp. Med. , vol.178 , pp. 1801-1806
    • Lin, H.1    Boiling, S.F.2    Linsley, P.S.3
  • 53
    • 0029851220 scopus 로고    scopus 로고
    • Blockade of multiple co-stimulatory receptors induces hyporesponsiveness. Inhibition of CD2 plus CD28 pathways
    • Woodward JE, Qin L, Chavin KD et al. Blockade of multiple co-stimulatory receptors induces hyporesponsiveness. Inhibition of CD2 plus CD28 pathways. Transplantation 62, 1011-1018 (1996).
    • (1996) Transplantation , vol.62 , pp. 1011-1018
    • Woodward, J.E.1    Qin, L.2    Chavin, K.D.3
  • 54
    • 15844404353 scopus 로고    scopus 로고
    • Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways
    • Larsen CP, Elwood ET, Alexander DZ et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 381, 434-438 (1996).
    • (1996) Nature , vol.381 , pp. 434-438
    • Larsen, C.P.1    Elwood, E.T.2    Alexander, D.Z.3
  • 55
    • 0029898878 scopus 로고    scopus 로고
    • Suppression of murine allergic contact dermatitis by CTLA4Ig. Tolerance induction of Th2 responses requires additional blockade of CD40-ligand
    • Tang A, Judge TA, Nickoloff BJ, Turka LA. Suppression of murine allergic contact dermatitis by CTLA4Ig. Tolerance induction of Th2 responses requires additional blockade of CD40-ligand. J. Immunol. 157, 117-125 (1996).
    • (1996) J. Immunol. , vol.157 , pp. 117-125
    • Tang, A.1    Judge, T.A.2    Nickoloff, B.J.3    Turka, L.A.4
  • 56
    • 0037469060 scopus 로고    scopus 로고
    • Induction of immunologic tolerance to cardiac allograft by simultaneous blockade of inducible co-stimulator and cytotoxic T-lymphocyte antigen 4 pathway
    • Kosuge H, Suzuki J, Gotoh R et al. Induction of immunologic tolerance to cardiac allograft by simultaneous blockade of inducible co-stimulator and cytotoxic T-lymphocyte antigen 4 pathway. Transplantation 75, 1374-1379 (2003).
    • (2003) Transplantation , vol.75 , pp. 1374-1379
    • Kosuge, H.1    Suzuki, J.2    Gotoh, R.3
  • 57
    • 10744223143 scopus 로고    scopus 로고
    • Simultaneous blockade of co-stimulatory signals, CD28 and ICOS, induced a stable tolerance in rat heart transplantation
    • Guo L, Fujino M, Kimura H et al. Simultaneous blockade of co-stimulatory signals, CD28 and ICOS, induced a stable tolerance in rat heart transplantation. Tanspl. Immunol. 12, 41-48 (2003).
    • (2003) Tanspl. Immunol. , vol.12 , pp. 41-48
    • Guo, L.1    Fujino, M.2    Kimura, H.3
  • 59
    • 0030966217 scopus 로고    scopus 로고
    • Induction of peripheral T-cell tolerance in vivo requires CTLA-4 engagement
    • Perez VL, Parijs LV, Biuckians A et al. Induction of peripheral T-cell tolerance in vivo requires CTLA-4 engagement. Immunity 6, 411-417 (1997).
    • (1997) Immunity , vol.6 , pp. 411-417
    • Perez, V.L.1    Parijs, L.V.2    Biuckians, A.3
  • 60
    • 10744226680 scopus 로고    scopus 로고
    • Transplantation tolerance through enhanced CTLA-4 expression
    • Ariyan C, Salvalaggio P, Fecteau S et al. Transplantation tolerance through enhanced CTLA-4 expression. J. Immunol. 171, 5673-5677 (2003).
    • (2003) J. Immunol. , vol.171 , pp. 5673-5677
    • Ariyan, C.1    Salvalaggio, P.2    Fecteau, S.3
  • 62
    • 2942586924 scopus 로고    scopus 로고
    • CTLA-4 regulates expansion and differentiation of Th1 cells following induction of peripheral T-cell tolerance
    • Eagar TN, Turley DM, Padilla J et al. CTLA-4 regulates expansion and differentiation of Th1 cells following induction of peripheral T-cell tolerance. J. Immunol. 172, 7442-7450 (2004).
    • (2004) J. Immunol. , vol.172 , pp. 7442-7450
    • Eagar, T.N.1    Turley, D.M.2    Padilla, J.3
  • 63
    • 0033557716 scopus 로고    scopus 로고
    • The role of CD80, CD86, and CTLA4 in alloimmune responses and the induction of long-term allograft survival
    • Judge TA, Wu Z, Zheng XG et al. The role of CD80, CD86, and CTLA4 in alloimmune responses and the induction of long-term allograft survival. J. Immunol. 162, 1947-1951 (1999).
    • (1999) J. Immunol. , vol.162 , pp. 1947-1951
    • Judge, T.A.1    Wu, Z.2    Zheng, X.G.3
  • 64
    • 0036852170 scopus 로고    scopus 로고
    • CTLA-4-Ig regulates tryptophan catabolism in vivo
    • Grohmann U, Orabona C, Fallarino F et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nature Immunol. 3, 1097-1101 (2002).
    • (2002) Nature Immunol. , vol.3 , pp. 1097-1101
    • Grohmann, U.1    Orabona, C.2    Fallarino, F.3
  • 65
    • 0038215374 scopus 로고    scopus 로고
    • Tolerance, DCs and tryptophan: Much ado about IDO
    • Grohmann U, Fallarino F, Puccetti P. Tolerance, DCs and tryptophan: much ado about IDO. Trends Immunol. 24, 242-248 (2003).
    • (2003) Trends Immunol. , vol.24 , pp. 242-248
    • Grohmann, U.1    Fallarino, F.2    Puccetti, P.3
  • 66
    • 0042591467 scopus 로고    scopus 로고
    • Induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T-cell clonal expansion
    • Mellor AL, Baban B, Chandler P et al. Induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T-cell clonal expansion. J. Immunol. 171, 1652-1655 (2003).
    • (2003) J. Immunol. , vol.171 , pp. 1652-1655
    • Mellor, A.L.1    Baban, B.2    Chandler, P.3
  • 67
    • 1642396607 scopus 로고    scopus 로고
    • +) T-cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells
    • +) T-cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells. J. Immunol. 172, 4100-4110 (2004).
    • (2004) J. Immunol. , vol.172 , pp. 4100-4110
    • Munn, D.H.1    Sharma, M.D.2    Mellor, A.L.3
  • 69
    • 3242875233 scopus 로고    scopus 로고
    • Technology evaluation: Abatacept, Bristol-Myers Squibb
    • Dumont FJ. Technology evaluation: abatacept, Bristol-Myers Squibb. Curr. Opin. Mol. Ther. 6, 318-330 (2004).
    • (2004) Curr. Opin. Mol. Ther. , vol.6 , pp. 318-330
    • Dumont, F.J.1
  • 70
    • 0035884819 scopus 로고    scopus 로고
    • An antagonist IL-15/Fc protein prevents costimulation blockade-resistant rejection
    • Ferrari-Lacraz S, Zheng XX, Kim YS et al. An antagonist IL-15/Fc protein prevents costimulation blockade-resistant rejection. J. Immunol. 167, 3478-3485 (2001).
    • (2001) J. Immunol. , vol.167 , pp. 3478-3485
    • Ferrari-Lacraz, S.1    Zheng, X.X.2    Kim, Y.S.3
  • 71
    • 0036467337 scopus 로고    scopus 로고
    • The role of the IL-2 pathway in costimulation blockade-resistant rejection of allografts
    • Jones TR, Ha J, Williams MA et al. The role of the IL-2 pathway in costimulation blockade-resistant rejection of allografts. J. Immunol. 168, 1123-1130 (2002).
    • (2002) J. Immunol. , vol.168 , pp. 1123-1130
    • Jones, T.R.1    Ha, J.2    Williams, M.A.3
  • 72
    • 0036023131 scopus 로고    scopus 로고
    • CTLA4Ig combined with anti-LFA-1 prolongs cardiac allograft survival indefinitely
    • Corbascio M, Ekstrand H, Osterholm C et al. CTLA4Ig combined with anti-LFA-1 prolongs cardiac allograft survival indefinitely. Transpl. Immunol. 10, 55-61 (2002).
    • (2002) Transpl. Immunol. , vol.10 , pp. 55-61
    • Corbascio, M.1    Ekstrand, H.2    Osterholm, C.3
  • 73
    • 0345164351 scopus 로고    scopus 로고
    • Combined costimulation blockade plus rapamycin but not cyclosporine produces permanent engraftment
    • Li Y, Zheng XX, Li XC, Zand MS, Strom TB. Combined costimulation blockade plus rapamycin but not cyclosporine produces permanent engraftment. Transplantation 66, 1387-1388 (1998).
    • (1998) Transplantation , vol.66 , pp. 1387-1388
    • Li, Y.1    Zheng, X.X.2    Li, X.C.3    Zand, M.S.4    Strom, T.B.5
  • 74
    • 1642412617 scopus 로고    scopus 로고
    • The antagonism of calcineurin inhibitors and costimulatory blockers: Fact or fiction?
    • Izawa A, Sayegh MH, Chandraker A. The antagonism of calcineurin inhibitors and costimulatory blockers: fact or fiction? Tansplant. Proc. 36, S570-S573 (2004).
    • (2004) Tansplant. Proc. , vol.36
    • Izawa, A.1    Sayegh, M.H.2    Chandraker, A.3
  • 75
    • 0030051268 scopus 로고    scopus 로고
    • Chronic cardiac rejection in the LEW to F344 rat model. Blockade of CD28-B7 costimulation by CTLA4Ig modulates T-cell and macrophage activation and attenuates arteriosclerosis
    • Russell ME, Hancock WW, Akalin E et al. Chronic cardiac rejection in the LEW to F344 rat model. Blockade of CD28-B7 costimulation by CTLA4Ig modulates T-cell and macrophage activation and attenuates arteriosclerosis. J. Clin. Invest. 97, 833-838 (1996).
    • (1996) J. Clin. Invest. , vol.97 , pp. 833-838
    • Russell, M.E.1    Hancock, W.W.2    Akalin, E.3
  • 76
    • 0032103321 scopus 로고    scopus 로고
    • Late blockade of T-cell costimulation interrupts progression of experimental chronic allograft rejection
    • Chandraker A, Azuma H, Nadeau K et al. late blockade of T-cell costimulation interrupts progression of experimental chronic allograft rejection. J. Clin. Invest. 101, 2309-2318 (1998).
    • (1998) J. Clin. Invest. , vol.101 , pp. 2309-2318
    • Chandraker, A.1    Azuma, H.2    Nadeau, K.3
  • 77
    • 0035101515 scopus 로고    scopus 로고
    • CD28-B7-mediated T-cell costimulation in chronic cardiac allograft rejection: Differential role of B7-1 in initiation versus progression of graft arteriosclerosis
    • Kim KS, Denton MD, Chandraker A et al. CD28-B7-mediated T-cell costimulation in chronic cardiac allograft rejection: differential role of B7-1 in initiation versus progression of graft arteriosclerosis. Am. J. Pathol. 158, 977-986 (2001).
    • (2001) Am. J. Pathol. , vol.158 , pp. 977-986
    • Kim, K.S.1    Denton, M.D.2    Chandraker, A.3
  • 78
    • 0030944223 scopus 로고    scopus 로고
    • Importance of the CD28/B7 co-stimulatory pathway in the development of chronic ductopenic rejection in a new model of orthotopic rat liver allotransplantation
    • Mark W, Hechenleitner P, Sayegh MH, Hancock WW, Candinas D. Importance of the CD28/B7 co-stimulatory pathway in the development of chronic ductopenic rejection in a new model of orthotopic rat liver allotransplantation. Transplant. Proc. 29, 1029 (1997).
    • (1997) Transplant. Proc. , vol.29 , pp. 1029
    • Mark, W.1    Hechenleitner, P.2    Sayegh, M.H.3    Hancock, W.W.4    Candinas, D.5
  • 80
    • 0029125813 scopus 로고
    • Acute graft-versus-host reaction can be aborted by blockade of costimulatory molecules
    • Hakim FT, Cepeda R, Gray GS, June CH, Abe R. Acute graft-versus-host reaction can be aborted by blockade of costimulatory molecules. J. Immunol. 155, 1757-1766 (1995).
    • (1995) J. Immunol. , vol.155 , pp. 1757-1766
    • Hakim, F.T.1    Cepeda, R.2    Gray, G.S.3    June, C.H.4    Abe, R.5
  • 81
    • 2442689006 scopus 로고    scopus 로고
    • Advances in the prevention of graft-versus-host disease after hematopoietic cell transplantation
    • Anasetti C. Advances in the prevention of graft-versus-host disease after hematopoietic cell transplantation. Transplantation 77, S79-SS83 (2004).
    • (2004) Transplantation , vol.77
    • Anasetti, C.1
  • 82
    • 0033214355 scopus 로고    scopus 로고
    • Stable mixed hematopoietic chimerism in dogs given donor antigen, CTLA4Ig, and 100 cGy total body irradiation before and pharmacologic immunosuppression after marrow transplant
    • Storb R, Yu C, Zaucha JM et al. Stable mixed hematopoietic chimerism in dogs given donor antigen, CTLA4Ig, and 100 cGy total body irradiation before and pharmacologic immunosuppression after marrow transplant. Blood. 94, 2523-2529 (1999).
    • (1999) Blood , vol.94 , pp. 2523-2529
    • Storb, R.1    Yu, C.2    Zaucha, J.M.3
  • 83
    • 0031307384 scopus 로고    scopus 로고
    • Immunosuppressive effects of human CTLA4Ig in a non-human primate model of allogeneic pancreatic islet transplantation
    • Levisetti MG, Padrid PA, Szot GL et al. Immunosuppressive effects of human CTLA4Ig in a non-human primate model of allogeneic pancreatic islet transplantation. J. Immunol. 159, 5187-5191 (1997).
    • (1997) J. Immunol. , vol.159 , pp. 5187-5191
    • Levisetti, M.G.1    Padrid, P.A.2    Szot, G.L.3
  • 84
    • 12644262358 scopus 로고    scopus 로고
    • CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates
    • Kirk AD, Harlan DM, Armstrong NN et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc. Natl Acad. Sci USA. 94, 8789-8794 (1997).
    • (1997) Proc. Natl. Acad. Sci. USA , vol.94 , pp. 8789-8794
    • Kirk, A.D.1    Harlan, D.M.2    Armstrong, N.N.3
  • 85
    • 0037108717 scopus 로고    scopus 로고
    • Anti-CD40 therapy extends renal allograft survival in rhesus macaques
    • Pearson TC, Trambley J, Odom K et al. Anti-CD40 therapy extends renal allograft survival in rhesus macaques. Transplantation 74, 933-940 (2002).
    • (2002) Transplantation , vol.74 , pp. 933-940
    • Pearson, T.C.1    Trambley, J.2    Odom, K.3
  • 86
    • 0032077806 scopus 로고    scopus 로고
    • Prolongation of cardiac graft survival with anti-CD4Ig plus hCTLA4Ig in primates
    • Krieger NR, Yuh D, Mcintyre WB et al. Prolongation of cardiac graft survival with anti-CD4Ig plus hCTLA4Ig in primates. J. Surg. Res. 76, 174-178 (1998).
    • (1998) J. Surg. Res. , vol.76 , pp. 174-178
    • Krieger, N.R.1    Yuh, D.2    Mcintyre, W.B.3
  • 87
    • 0036061575 scopus 로고    scopus 로고
    • Calcineurin inhibitor-free CD28 blockade-based protocol protects allogeneic islets in nonhuman primates
    • Adams AB, Shirasugi N, Durham MM et al. Calcineurin inhibitor-free CD28 blockade-based protocol protects allogeneic islets in nonhuman primates. Diabetes 51, 265-270 (2002).
    • (2002) Diabetes , vol.51 , pp. 265-270
    • Adams, A.B.1    Shirasugi, N.2    Durham, M.M.3
  • 88
    • 0033519661 scopus 로고    scopus 로고
    • Transplantation of anergic histoincompatible bone marrow allografts
    • Guinan EC, Boussiotis VA, Neubertg D et al. Transplantation of anergic histoincompatible bone marrow allografts. N. Engl. J. Med. 340, 1704-1714 (1999).
    • (1999) N. Engl. J. Med. , vol.340 , pp. 1704-1714
    • Guinan, E.C.1    Boussiotis, V.A.2    Neubertg, D.3
  • 89
    • 9744286455 scopus 로고    scopus 로고
    • Co-stimulation blockade with LEA29Y in renal transplant: Improved renal function and CV/metabolic profile at 6 months compared with cyclosporine
    • American Transplant Congress, Boston, USA. Abs. 1035
    • Nashan B, Grinyo J, Vincenti F et al. Co-stimulation blockade with LEA29Y in renal transplant: improved renal function and CV/metabolic profile at 6 months compared with cyclosporine. American Transplant Congress, Boston, USA. Abs. 1035, (2004).
    • (2004)
    • Nashan, B.1    Grinyo, J.2    Vincenti, F.3
  • 90
    • 9744264217 scopus 로고    scopus 로고
    • Co-stimulation blockade with LEA29Y in a calcineurin inhibitor free maintenance regimen in renal transplant: 6-month efficacy and safety
    • American Transplant Congress, Boston, USA Abs. 1037
    • Vincenti F, Muehlbacher F, Nashan B et al. Co-stimulation blockade with LEA29Y in a calcineurin inhibitor free maintenance regimen in renal transplant: 6-month efficacy and safety. American Transplant Congress, Boston, USA Abs. 1037, (2004).
    • (2004)
    • Vincenti, F.1    Muehlbacher, F.2    Nashan, B.3
  • 91
    • 0031253956 scopus 로고    scopus 로고
    • Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways
    • Daikh DI, Finck BK, Linsley PS, Hollenbaugh D, Wofsy D. Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways. J. Immunol. 159, 3104-3108 (1997).
    • (1997) J. Immunol. , vol.159 , pp. 3104-3108
    • Daikh, D.I.1    Finck, B.K.2    Linsley, P.S.3    Hollenbaugh, D.4    Wofsy, D.5
  • 92
    • 0037083423 scopus 로고    scopus 로고
    • Mechanism of action of combined short-term CTLA4Ig and anti-CD40 ligand in murine systemic lupus erythematosus
    • Wang X, Huang W, Mihara M, Sinha J, Davidson A. Mechanism of action of combined short-term CTLA4Ig and anti-CD40 ligand in murine systemic lupus erythematosus. J. Immunol. 168, 2046-2053 (2002).
    • (2002) J. Immunol. , vol.168 , pp. 2046-2053
    • Wang, X.1    Huang, W.2    Mihara, M.3    Sinha, J.4    Davidson, A.5
  • 93
    • 0035284737 scopus 로고    scopus 로고
    • Reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide
    • Daikh DI, Wofsy D. Reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. J. Immunol. 166, 2913-1916 (2001).
    • (2001) J. Immunol. , vol.166 , pp. 1916-2913
    • Daikh, D.I.1    Wofsy, D.2
  • 94
    • 0037868032 scopus 로고    scopus 로고
    • Short term administration of costimulatory blockade and cyclophosphamide induces remission of systemic lupus erythematosus nephritis in NZB/W F1 mice by a mechanism downstream of renal immune complex deposition
    • Schiffer L, Sinha J, Wang X et al. Short term administration of costimulatory blockade and cyclophosphamide induces remission of systemic lupus erythematosus nephritis in NZB/W F1 mice by a mechanism downstream of renal immune complex deposition. J. Immunol. 171, 489-497 (2003).
    • (2003) J. Immunol. , vol.171 , pp. 489-497
    • Schiffer, L.1    Sinha, J.2    Wang, X.3
  • 95
    • 2342495275 scopus 로고    scopus 로고
    • Prevention of renal damage in murine lupus nephritis by CTLA-4Ig and cyclophosphamide
    • Cunnane G, Chan OT, Cassafer G et al. Prevention of renal damage in murine lupus nephritis by CTLA-4Ig and cyclophosphamide. Arthritis Rheum 50, 1539-1548 (2004).
    • (2004) Arthritis Rheum. , vol.50 , pp. 1539-1548
    • Cunnane, G.1    Chan, O.T.2    Cassafer, G.3
  • 96
    • 0029849012 scopus 로고    scopus 로고
    • Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: Requirement for both B7-I and B7-2
    • Webb LM, Walmsley MJ, Feldmann M. Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: requirement for both B7-I and B7-2. Eur. J. Immunol. 26, 2320-2328 (1996).
    • (1996) Eur. J. Immunol. , vol.26 , pp. 2320-2328
    • Webb, L.M.1    Walmsley, M.J.2    Feldmann, M.3
  • 97
    • 0037420518 scopus 로고    scopus 로고
    • Psoriasis
    • Lebwohl M. Psoriasis. Lancet 361, 1197-1204 (2003).
    • (2003) Lancet , vol.361 , pp. 1197-1204
    • Lebwohl, M.1
  • 98
    • 0034605033 scopus 로고    scopus 로고
    • Blockade of T-lymphocyte costimulation with cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells
    • Abrams JR, Kelley SL, Hayes E et al. Blockade of T-lymphocyte costimulation with cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J. Exp. Med. 192, 681-693 (2000).
    • (2000) J. Exp. Med. , vol.192 , pp. 681-693
    • Abrams, J.R.1    Kelley, S.L.2    Hayes, E.3
  • 99
    • 0000415293 scopus 로고    scopus 로고
    • New concepts in the treatment of rheumatoid arthritis
    • Goldbach-Mansky R. Lipsky PE. New concepts in the treatment of rheumatoid arthritis. Ann. Rev. Med. 54, 197-216 (2003).
    • (2003) Ann. Rev. Med. , vol.54 , pp. 197-216
    • Goldbach-Mansky, R.1    Lipsky, P.E.2
  • 100
    • 0036275436 scopus 로고    scopus 로고
    • Costimulatory blockade in patients with rheumatoid arthritis: A pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion
    • Moreland LW, Alten R, Van Den Bosch F et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum. 46, 1470-1479 (2002).
    • (2002) Arthritis Rheum. , vol.46 , pp. 1470-1479
    • Moreland, L.W.1    Alten, R.2    Van Den Bosch, F.3
  • 101
    • 0242574700 scopus 로고    scopus 로고
    • Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig
    • Kremer JM, Westhovens R, Leon M et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N. Engl. J. Med. 349, 1907-1915 (2003).
    • (2003) N. Engl. J. Med. , vol.349 , pp. 1907-1915
    • Kremer, J.M.1    Westhovens, R.2    Leon, M.3
  • 102
    • 33645430269 scopus 로고    scopus 로고
    • CTLA4Ig (BMS-188667) in a phase IIb, multi-center, randomized, double-blind, placebo controlled study in rheumatoid arthritis patients receiving methrotexate showed correlation between the clinical response and key biomarkers
    • Abs. 0157
    • Emery P, Westhovens R, Moreland L et al. CTLA4Ig (BMS-188667) in a phase IIb, multi-center, randomized, double-blind, placebo controlled study in rheumatoid arthritis patients receiving methrotexate showed correlation between the clinical response and key biomarkers. Ann. Rheum. Dis. 62, Abs. 0157 (2003).
    • (2003) Ann. Rheum. Dis. , pp. 62
    • Emery, P.1    Westhovens, R.2    Moreland, L.3
  • 103
    • 33645441119 scopus 로고    scopus 로고
    • Abatacept (CTLA4Ig) treatment increases the remission rate in rheumatoid arthritis patients refractory to methotrexate treatment
    • Westhovens R, Van Riel P, Sibilia J. et al. Abatacept (CTLA4Ig) treatment increases the remission rate in rheumatoid arthritis patients refractory to methotrexate treatment. Arthritis Res. Ther. 6, 86 (2004).
    • (2004) Arthritis Res. Ther. , vol.6 , pp. 86
    • Westhovens, R.1    Van Riel, P.2    Sibilia, J.3
  • 104
    • 33645440397 scopus 로고    scopus 로고
    • CTLA4Ig (BMS-188667), a co-stimulation blocker, improved physical function in patients with active rheumatoid arthritis using methotrexate
    • Abs. 0227
    • Tugwell P, Emery P, Li T et al. CTLA4Ig (BMS-188667), a co-stimulation blocker, improved physical function in patients with active rheumatoid arthritis using methotrexate. Ann. Rheum. Dis. 62, Abs. 0227 (2003).
    • (2003) Ann. Rheum. Dis. , pp. 62
    • Tugwell, P.1    Emery, P.2    Li, T.3
  • 105
    • 4244023444 scopus 로고    scopus 로고
    • Impact on health-related quality of life following treatment with CTLA4Ig in patients with active rheumatoid arthritis using methotrexate
    • (Abs. 1377)
    • Emery P, Williams GR, Li T, Nuamah I, Becker JC. Impact on health-related quality of life following treatment with CTLA4Ig in patients with active rheumatoid arthritis using methotrexate. Arthritis Rheum. 46, S515 (Abs. 1377) (2002).
    • (2002) Arthritis Rheum. , vol.46
    • Emery, P.1    Williams, G.R.2    Li, T.3    Nuamah, I.4    Becker, J.C.5
  • 106
    • 33645426541 scopus 로고    scopus 로고
    • Improvement in health-related quality of life with treatment of CTLA4Ig (BMS-188667), a co-stimulation blocker, over one year in patients with active rheumatoid arthritis using methotrexate
    • American College of Rheumatology Meeting, Orlando, Florida, USA. Abs. 998
    • Emery P, Russell A, Kremer J. et al. Improvement in health-related quality of life with treatment of CTLA4Ig (BMS-188667), a co-stimulation blocker, over one year in patients with active rheumatoid arthritis using methotrexate. American College of Rheumatology Meeting, Orlando, Florida, USA. Abs. 998 (2003).
    • (2003)
    • Emery, P.1    Russell, A.2    Kremer, J.3
  • 107
    • 0013218378 scopus 로고    scopus 로고
    • A pilot, multicenter, randomized, double-blind, placebo-controlled (study) of a costimulation blocker CTLA4Ig (2 mg/kg) given monthly in combination with etanercept in active rheumatoid arthritis
    • (Abs. 464)
    • Weinblatt M, Schiff M, Goldmann M et al. A pilot, multicenter, randomized, double-blind, placebo-controlled (study) of a costimulation blocker CTLA4Ig (2 mg/kg) given monthly in combination with etanercept in active rheumatoid arthritis. Arthritis Rheum. 46, S204 (Abs. 464) (2002).
    • (2002) Arthritis Rheum. , vol.46
    • Weinblatt, M.1    Schiff, M.2    Goldmann, M.3
  • 108
    • 33645430269 scopus 로고    scopus 로고
    • CTLA4-Ig (BMS-188667) in a Phase IIb, multi-center, randomized, double-blind, placebo controlled study in rheumatoid arthritis patients receiving etanercept: Association between clinical response and key biomarkers
    • Abs. 0225
    • Schiff M, Genoves M, Nuamah I, Becker J, Weinblatt M. CTLA4-Ig (BMS-188667) in a Phase IIb, multi-center, randomized, double-blind, placebo controlled study in rheumatoid arthritis patients receiving etanercept: association between clinical response and key biomarkers. Ann. Rheum. Dis. 62, Abs. 0225 (2003).
    • (2003) Ann. Rheum. Dis. , pp. 62
    • Schiff, M.1    Genoves, M.2    Nuamah, I.3    Becker, J.4    Weinblatt, M.5
  • 109
    • 4244023469 scopus 로고    scopus 로고
    • Improvement in health-related quality of life in patients with active rheumatoid arthritis: CTLA4Ig combined with etanercept compared with etanercept plus placebo
    • Abs. 1376
    • Emery P, Williams GR, Li T, Breazna A, Becker JC. Improvement in health-related quality of life in patients with active rheumatoid arthritis: CTLA4Ig combined with etanercept compared with etanercept plus placebo. Arthritis Rheumat. 46, S514, Abs. 1376 (2002).
    • (2002) Arthritis Rheumat. , vol.46
    • Emery, P.1    Williams, G.R.2    Li, T.3    Breazna, A.4    Becker, J.C.5
  • 110
    • 12144290293 scopus 로고    scopus 로고
    • Calcineurin imposes T-cell unresponsiveness through targeted protelysis of signaling proteins
    • Heissmeyer V, Macian F, Im SH et al. Calcineurin imposes T-cell unresponsiveness through targeted protelysis of signaling proteins. Nature Immunol. 5, 255-265 (2004).
    • (2004) Nature Immunol. , vol.5 , pp. 255-265
    • Heissmeyer, V.1    Macian, F.2    Im, S.H.3
  • 111
    • 0030912016 scopus 로고    scopus 로고
    • CTLA4-Ig treatment prolongs rat orthotopic liver graft survival
    • Tu Y, Rehman A, Flye MW. CTLA4-Ig treatment prolongs rat orthotopic liver graft survival. Transpl. Proc. 29, 1036-1037 (1997).
    • (1997) Transpl. Proc. , vol.29 , pp. 1036-1037
    • Tu, Y.1    Rehman, A.2    Flye, M.W.3
  • 112
    • 0030447936 scopus 로고    scopus 로고
    • Induction of tolerance to small bowel allografts in high-responder rats by combining anti-CD4 with CTLA4Ig
    • Yin D, Sankary HN, Williams J, Kreiger N, Fathman Cg. Induction of tolerance to small bowel allografts in high-responder rats by combining anti-CD4 with CTLA4Ig. Transplantation 62, 1537-1539 (1996).
    • (1996) Transplantation , vol.62 , pp. 1537-1539
    • Yin, D.1    Sankary, H.N.2    Williams, J.3    Kreiger, N.4    Fathman, Cg.5
  • 113
    • 0028952480 scopus 로고
    • Soluble CTLA4Ig modifies parameters of acute inflammation in rat lung allograft rejection without altering lymphocytic infiltration or transcription of key cytokines
    • Matsumura Y, Zuo XJ, Prehn J et al. Soluble CTLA4Ig modifies parameters of acute inflammation in rat lung allograft rejection without altering lymphocytic infiltration or transcription of key cytokines. Transplantation 59, 551-558 (1995).
    • (1995) Transplantation , vol.59 , pp. 551-558
    • Matsumura, Y.1    Zuo, X.J.2    Prehn, J.3
  • 114
    • 0037084322 scopus 로고    scopus 로고
    • Feasibility of immunosuppression in composite tissue allografts by systemic administration of CTLA4Ig
    • Iwasaki N, Gohda T, Yoshioka C et al. Feasibility of immunosuppression in composite tissue allografts by systemic administration of CTLA4Ig. Transplantation 73, 334-340 (2002).
    • (2002) Transplantation , vol.73 , pp. 334-340
    • Iwasaki, N.1    Gohda, T.2    Yoshioka, C.3
  • 115
    • 0029162499 scopus 로고
    • Collagen-induced arthritis in the BB rat. Prevention of disease by treatment with CTLA-4-Ig
    • Knoerzer DB, Karr RW, Schwartz BD, Mengle-Gaw LJ. Collagen-induced arthritis in the BB rat. Prevention of disease by treatment with CTLA-4-Ig. J. Clin. Invest. 96, 987-993 (1995).
    • (1995) J. Clin. Invest. , vol.96 , pp. 987-993
    • Knoerzer, D.B.1    Karr, R.W.2    Schwartz, B.D.3    Mengle-Gaw, L.J.4
  • 116
    • 0028868424 scopus 로고
    • CD28-B7 costimulatory blockade by CTLA4Ig prevents actively induced experimental autoimmune encephalomyelitis and inhibits Th1 but spares Th2 cytokines in the central nervous system
    • Khoury SJ, Akalin E, Chandraker A et al. CD28-B7 costimulatory blockade by CTLA4Ig prevents actively induced experimental autoimmune encephalomyelitis and inhibits Th1 but spares Th2 cytokines in the central nervous system. J. Immunol. 155, 4521-4524 (1995).
    • (1995) J. Immunol. , vol.155 , pp. 4521-4524
    • Khoury, S.J.1    Akalin, E.2    Chandraker, A.3
  • 117
    • 0028900297 scopus 로고
    • Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the non-obese diabetic mouse
    • Lenschow DJ, Ho SC, Sattar H et al. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the non-obese diabetic mouse. J. Exp. Med. 181, 1145-1155 (1995).
    • (1995) J. Exp. Med. , vol.181 , pp. 1145-1155
    • Lenschow, D.J.1    Ho, S.C.2    Sattar, H.3
  • 119
    • 4644285392 scopus 로고    scopus 로고
    • E3 ubiquitin ligases as T-cell anergy factors
    • Mueller DL. E3 ubiquitin ligases as T-cell anergy factors. Nature Immunol. 5, 883-890 (2004).
    • (2004) Nature Immunol. , vol.5 , pp. 883-890
    • Mueller, D.L.1
  • 120
    • 1842607447 scopus 로고    scopus 로고
    • New immunosuppressive strategies in renal transplant recipients
    • Fischereder M, Kretzler M. New immunosuppressive strategies in renal transplant recipients. J. Nephrol. 17, 9-18 (2004).
    • (2004) J. Nephrol. , vol.17 , pp. 9-18
    • Fischereder, M.1    Kretzler, M.2
  • 121
    • 1642347770 scopus 로고    scopus 로고
    • FTY720 immunomodulation: Optimism for improved transplant regimens
    • Ferguson R. FTY720 immunomodulation: optimism for improved transplant regimens. Transpl. Proc. 36, S549-S553 (2004).
    • (2004) Transpl. Proc. , vol.36
    • Ferguson, R.1
  • 122
    • 3042743990 scopus 로고    scopus 로고
    • FTY720: Sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function
    • Brinkmann V, Cyster JG, Hla T. FTY720: Sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. Am. J. Transplant. 4, 1019-1025 (2004).
    • (2004) Am. J. Transplant. , vol.4 , pp. 1019-1025
    • Brinkmann, V.1    Cyster, J.G.2    Hla, T.3
  • 123
    • 0036285240 scopus 로고    scopus 로고
    • Combination treatment with FTY720 and CTLA4IgG preserves the respiratory epithelium and prevents obliterative disease in a murine airway model
    • Konishi K, Inobe M, Yamada A et al. Combination treatment with FTY720 and CTLA4IgG preserves the respiratory epithelium and prevents obliterative disease in a murine airway model. J. Heart Lung Transplant. 21, 692-700 (2002).
    • (2002) J. Heart Lung Transplant. , vol.21 , pp. 692-700
    • Konishi, K.1    Inobe, M.2    Yamada, A.3
  • 124
    • 0242332186 scopus 로고    scopus 로고
    • Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor
    • Changelian PS, Flanagan ME, Ball DJ et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 302, 875-878 (2003).
    • (2003) Science , vol.302 , pp. 875-878
    • Changelian, P.S.1    Flanagan, M.E.2    Ball, D.J.3
  • 126
    • 0038690324 scopus 로고    scopus 로고
    • Clinical trials of transplant tolerance: Slow but steady progress
    • Matthews JB, Ramos E, Bluestone JA. Clinical trials of transplant tolerance: slow but steady progress. Am. J. Transplant. 3, 794-803 (2003).
    • (2003) Am. J. Transplant. , vol.3 , pp. 794-803
    • Matthews, J.B.1    Ramos, E.2    Bluestone, J.A.3
  • 127
    • 3042722261 scopus 로고    scopus 로고
    • Exploiting tolerance processes in transplantation
    • Waldmann H, Cobbold S. Exploiting tolerance processes in transplantation. Science 305, 209-212 (2004).
    • (2004) Science , vol.305 , pp. 209-212
    • Waldmann, H.1    Cobbold, S.2
  • 128
    • 3042819498 scopus 로고    scopus 로고
    • Surrogate markers for long-term renal allograft survival
    • Hariharan S, Kasiske B, Matas A et al. Surrogate markers for long-term renal allograft survival. Am. J. Transplant. 4, 1179-1183 (2004).
    • (2004) Am. J. Transplant. , vol.4 , pp. 1179-1183
    • Hariharan, S.1    Kasiske, B.2    Matas, A.3
  • 130
    • 1642321113 scopus 로고    scopus 로고
    • Revival of the regulatory T-cell: New targets for drug development
    • Sutmuller RP, Offringa R, Melief CJ. Revival of the regulatory T-cell: new targets for drug development. Drug Discov. Today 9, 310-316 (2004).
    • (2004) Drug Discov. Today , vol.9 , pp. 310-316
    • Sutmuller, R.P.1    Offringa, R.2    Melief, C.J.3
  • 132
    • 12144288178 scopus 로고    scopus 로고
    • Efficacy and safety of ABI793, a novel human anti-human CD154 monoclonal antibody, in cynomolgus monkey renal allotransplantation
    • Schuler W, Bigaud M, Brinkmann V, et al. Efficacy and safety of ABI793, a novel human anti-human CD154 monoclonal antibody, in cynomolgus monkey renal allotransplantation. Transplantation 77, 717-726 (2004).
    • (2004) Transplantation , vol.77 , pp. 717-726
    • Schuler, W.1    Bigaud, M.2    Brinkmann, V.3
  • 133
    • 4344586455 scopus 로고    scopus 로고
    • CD154 blockade for induction of mixed chimerism and prolonged renal allograft survival in nonhuman primates
    • Kawai T, Sogawa H, Boskovic S et al. CD154 blockade for induction of mixed chimerism and prolonged renal allograft survival in nonhuman primates. Am. J. Transplant. 4, 1391-1398 (2004).
    • (2004) Am. J. Transplant. , vol.4 , pp. 1391-1398
    • Kawai, T.1    Sogawa, H.2    Boskovic, S.3
  • 134
    • 10744220010 scopus 로고    scopus 로고
    • Thrombophilia associated with anti-CD154 monoclonal antibody treatment and its prophylaxis in nonhuman primates
    • Koyama I, Kawai T, Andrews D et al. Thrombophilia associated with anti-CD154 monoclonal antibody treatment and its prophylaxis in nonhuman primates. Transplantation 77, 460-462 (2004).
    • (2004) Transplantation , vol.77 , pp. 460-462
    • Koyama, I.1    Kawai, T.2    Andrews, D.3
  • 135
    • 3342935958 scopus 로고    scopus 로고
    • Anti-CD3 antibodies: Towards clinical antigen-specific immunomodulation
    • Chatenoud L. Anti-CD3 antibodies: towards clinical antigen-specific immunomodulation. Curr. Opin. Pharmacol. 4, 403-437 (2004).
    • (2004) Curr. Opin. Pharmacol. , vol.4 , pp. 403-437
    • Chatenoud, L.1
  • 136
    • 3042847542 scopus 로고    scopus 로고
    • Immune therapy for autoimmune diseases
    • Steinman L. Immune therapy for autoimmune diseases. Science 305, 212-216 (2004).
    • (2004) Science , vol.305 , pp. 212-216
    • Steinman, L.1
  • 137
    • 0037413468 scopus 로고    scopus 로고
    • Natalizumab for active Crohn's disease
    • Ghosh S, Goldin E, Gordon FH et al. Natalizumab for active Crohn's disease. N. Engl. J. Med. 348, 24-32 (2003).
    • (2003) N. Engl. J. Med. , vol.348 , pp. 24-32
    • Ghosh, S.1    Goldin, E.2    Gordon, F.H.3
  • 138
    • 0037413467 scopus 로고    scopus 로고
    • A controlled trial of natalizumab for relapsing multiple sclerosis
    • Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 348, 15-23 (2003).
    • (2003) N. Engl. J. Med. , vol.348 , pp. 15-23
    • Miller, D.H.1    Khan, O.A.2    Sheremata, W.A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.